Skip to main content

Table 3 Predictors of response for patients with HCV genotype 1 infection

From: Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center “real-life” cohort

  SVR 12 Relapse p value
  total: 74 % (56) total: 26 % (20)  
Age <65 years 95 % (53) 85 % (17) 0.1698
Age ≥65 years 5 % (3) 15 % (3)
Female 34 % (19) 20 % (4) 0.2445
Male 66 % (37) 80 % (16)
Non-cirrhotic 64 % (36) 35 % (7) 0.0233
Cirrhotic 36 % (20) 65 % (13)
Treatment naive 52 % (29) 45 % (9) 0.6024
Treatment experienced 48 % (27) 55 % (11)
HCV-RNA <6 (10E6 IU ml-1) at baseline 79 % (44) 85 % (17) 0.5352
HCV-RNA ≥6 (10E6 IU ml-1) at baseline 21 % (12) 15 % (3)
HCV-RNA <12 (IU ml-1) after 4 weeks of treatment 70 % (39) 35 % (7) 0.0065
HCV-RNA ≥12 (IU ml-1) after 4 weeks of treatment 30 % (17) 65 % (13)
Platelets <100 (10E3 μl-1) at baseline 18 % (10) 30 % (6) 0.2529
Platelets ≥100 (10E3 μl-1) at baseline 82 % (46) 70 % (14)
  1. Data are expressed as percent (number)
  2. SVR 12 sustained virological response at 12 weeks after end of treatment
  3. Boldface data statistically significant